Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2019

28.10.2019 | short review

Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract

Presentation highlights from the ASCO 2019 Congress

verfasst von: MD Assoc. Prof. Georg C. Hutterer, MD Assoc. Prof. Martin Pichler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Three important oral presentations from the ASCO 2019 congress concerning advanced and metastatic urothelial carcinoma of the urinary bladder and the upper tract are highlighted and their potential clinical implications for the improvement of systemic therapies in respective patients are discussed. Enfortumab vedotin, an antibody-drug conjugate targeting nectin‑4, demonstrated a clinically meaningful objective response rate in patients with prior platinum-based chemotherapy and checkpoint inhibition, in a phase II trial. A high unmet need in this heavily pretreated patient population combined with good tolerability and manageable safety profile support a submission to the FDA (US Food and Drug Administration) for accelerated approval. The early use of an immunotherapeutic approach via pembrolizumab in patients with metastatic urothelial carcinoma as “switch maintenance” therapy achieved an objective response rate of 22% vs. 12% in the placebo arm in a phase II trial. Pembrolizumab was shown to potentially “deepen” responses achieved with first-line chemotherapy. Moreover, switch maintenance pembrolizumab was able to significantly delay disease progression, whereby a better characterized role of switch maintenance programmed death‑1 blockade will be refined by currently ongoing phase III trials. Based on data showing that angiogenesis plays an important role in urothelial carcinoma growth and progression, a randomized, placebo-controlled phase III trial tested whether the addition of bevacizumab to gemcitabine + cisplatin combination chemotherapy is able to improve overall survival in metastatic urothelial carcinoma patients in first-line therapy. This trial was negative regarding its primary endpoint; thus, currently the standard of care remains cisplatin-based chemotherapy without the addition of biologic agents in advanced or metastatic urothelial carcinoma.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. CrossRef
2.
Zurück zum Zitat Liao RS, Gupta M, Schwen ZR, et al. Comparison of pathological stage in patients treated with and without Neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol. 2018;200(1):68–73. CrossRef Liao RS, Gupta M, Schwen ZR, et al. Comparison of pathological stage in patients treated with and without Neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol. 2018;200(1):68–73. CrossRef
3.
Zurück zum Zitat von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. CrossRef von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. CrossRef
4.
Zurück zum Zitat Bellmunt J, Bajorin DF. Pembrolizumab for advanced urothelial carcinoma. N Engl J Med. 2017;376(23):2304. PubMed Bellmunt J, Bajorin DF. Pembrolizumab for advanced urothelial carcinoma. N Engl J Med. 2017;376(23):2304. PubMed
5.
Zurück zum Zitat Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57. CrossRef Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57. CrossRef
6.
Zurück zum Zitat Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–77. CrossRef Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–77. CrossRef
8.
Zurück zum Zitat Petrylak DP, Balar AV, O’Donnell PH, McGregor BA, Heath EI, Yu EY et al. EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. J Clin Oncol. 2019;37(18_suppl):4505. CrossRef Petrylak DP, Balar AV, O’Donnell PH, McGregor BA, Heath EI, Yu EY et al. EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. J Clin Oncol. 2019;37(18_suppl):4505. CrossRef
9.
Zurück zum Zitat Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. CrossRef Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. CrossRef
10.
Zurück zum Zitat Galsky MD, Pal SK, Mortazavi A, Milowsky MI, George S, Gupta S et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. J Clin Oncol. 2019;37(15_suppl):4504. CrossRef Galsky MD, Pal SK, Mortazavi A, Milowsky MI, George S, Gupta S et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. J Clin Oncol. 2019;37(15_suppl):4504. CrossRef
11.
Zurück zum Zitat Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000;6(12):4866–73. PubMed Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000;6(12):4866–73. PubMed
12.
Zurück zum Zitat Canoğlu A, Göğüş C, Bedük Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol. 2004;36(3):401–5. CrossRef Canoğlu A, Göğüş C, Bedük Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol. 2004;36(3):401–5. CrossRef
13.
Zurück zum Zitat Bellmunt J, González-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin‑8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646–53. CrossRef Bellmunt J, González-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin‑8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646–53. CrossRef
14.
Zurück zum Zitat Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi45–vi9. PubMed Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi45–vi9. PubMed
15.
Zurück zum Zitat Rosenberg JE, Ballman KV, Halabi S, Watt C, Hahn OM, Steen PD et al. CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. J Clin Oncol. 2019;37(15_suppl):4503. CrossRef Rosenberg JE, Ballman KV, Halabi S, Watt C, Hahn OM, Steen PD et al. CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. J Clin Oncol. 2019;37(15_suppl):4503. CrossRef
Metadaten
Titel
Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract
Presentation highlights from the ASCO 2019 Congress
verfasst von
MD Assoc. Prof. Georg C. Hutterer
MD Assoc. Prof. Martin Pichler
Publikationsdatum
28.10.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00532-9

Weitere Artikel der Ausgabe 4/2019

memo - Magazine of European Medical Oncology 4/2019 Zur Ausgabe